The study about serum α-fetoprotein to predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma have found that the reduction of serum AFP level after anti-PD-1 treatment is associated with a good prognosis for advanced HCC (31). This evidence concerns the gene AFP and hepatocellular carcinoma.